Idoroenyi Amanam to Mutation
This is a "connection" page, showing publications Idoroenyi Amanam has written about Mutation.
Connection Strength
1.552
-
TP53 mutations are associated with CD19- relapse and inferior outcomes after blinatumomab in adults with ALL. Blood Adv. 2025 May 13; 9(9):2159-2172.
Score: 0.220
-
Risk prediction for clonal cytopenia: multicenter real-world evidence. Blood. 2024 Nov 07; 144(19):2033-2044.
Score: 0.212
-
Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study. Int J Mol Sci. 2024 Sep 23; 25(18).
Score: 0.210
-
Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Leuk Res. 2024 10; 145:107565.
Score: 0.209
-
High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy. Leuk Lymphoma. 2024 07; 65(7):1020-1023.
Score: 0.204
-
Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Ann Oncol. 2019 07 01; 30(7):1096-1103.
Score: 0.146
-
Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma. Am J Clin Oncol. 2019 04; 42(4):337-344.
Score: 0.144
-
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
Score: 0.133
-
Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS One. 2019; 14(11):e0224726.
Score: 0.037
-
Targeted Therapies in Non-small-Cell Lung Cancer. Cancer Treat Res. 2019; 178:3-43.
Score: 0.035